Coherus BioSciences Targets $200 Million Market for LOQTORZI in NPC

Published 7 hours agoCHRS

Coherus BioSciences Targets $200 Million Market for LOQTORZI in NPC

Coherus BioSciences has identified a substantial market opportunity for LOQTORZI, setting its sights on a $150 million to $200 million target in the nasopharyngeal carcinoma (NPC) arena. The treatment garnered FDA approval in January 2024, making it the first approved therapy for recurrent, locally advanced, or metastatic NPC, and was launched across all lines of therapy.

Several developments have aided LOQTORZI’s growth trajectory. In November 2024, the National Comprehensive Cancer Network updated its guidelines to bestow LOQTORZI with Preferred status for both first-line and second-line treatment settings. Additionally, the drug saw a significant boost in sales, reporting $7.5 million in net product sales for the fourth quarter of 2024—a 29% increase from the prior quarter—with annual sales reaching $19.1 million, according to GlobeNewswire.

Coherus continues to fortify its position in the market through strategic collaborations, including partnerships with Junshi Biosciences and INOVIO Pharmaceuticals. These alliances are pivotal in expanding LOQTORZI’s therapeutic applications and market footprint. Concurrently, Coherus is enhancing its oncology pipeline with innovative treatments such as casdozokitug and CHS-114, further positioning the company for future growth in the oncology sector.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Robinhood Buys WonderFi in $179 Million Deal to Expand Crypto Reach

Robinhood Buys WonderFi in $179 Million Deal to Expand Crypto Reach

13 minutes agoHOOD

Robinhood Markets has announced a significant expansion into the Canadian cryptocurrency market by acquiring WonderFi Technologies in an all-cash deal valued at C$250 million, or approximately $179 million. This strategic move prices WonderFi at C$0.36 per share, marking a 41% premium compared to its previous closing share price. According to Reuters, with this acquisition, Robinhood aims to fortify its international footprint and deepen its involvement in the burgeoning cryptocurrency sector. WonderFi, known for its popular platforms Bitbuy and Coinsquare, has shown impressive growth, processing over C$3.57 billion in trading volumes during fiscal year 2024—an increase of 28% from the prior year. This performance highlights the potential Robinhood sees in leveraging WonderFi's existing operations to capture a larger share of the crypto trading market in Canada. Despite the challenges and volatility often associated with cryptocurrencies, companies continue to see value in expanding their services to meet growing demand. In line with the acquisition, Robinhood plans to integrate WonderFi’s entire team into its Canadian operations, which already employs more than 140 people. This acquisition reflects a broader trend of increased activity in the crypto space, demonstrated by other significant deals such as Coinbase's $2.9 billion purchase of Deribit and Ripple's $1.25 billion acquisition of Hidden Road. By absorbing WonderFi, Robinhood positions itself to better serve its existing and new customer base in a competitive and quickly evolving market.

UnitedHealth CEO Resigns Amid Financial Uncertainty

UnitedHealth CEO Resigns Amid Financial Uncertainty

28 minutes agoUNH

UnitedHealth Group has faced a significant leadership change as CEO Andrew Witty announced his resignation, effective immediately, due to personal reasons. In response to this sudden vacancy, Stephen Hemsley, who previously led the company from 2006 to 2017, has been appointed as interim CEO. Reuters reported the decision comes as the healthcare giant navigates challenging financial circumstances. In a related move, UnitedHealth has suspended its financial forecast for 2025, attributing the decision to unexpectedly high medical costs, particularly from new beneficiaries in its Medicare Advantage plans. This development has spooked investors, causing the company's shares to tumble by 8% in premarket trading, as detailed by Reuters. Despite these challenges, UnitedHealth remains optimistic about the long-term prospects. The company aims to rebound and achieve growth by 2026. This strategic pause and leadership shift suggest a period of recalibration as UnitedHealth seeks to address current hurdles while positioning itself for future stability and expansion.

United Airlines Grapples with Operational Snags at Newark

United Airlines Grapples with Operational Snags at Newark

43 minutes agoUAL

United Airlines is currently navigating significant hurdles at Newark Liberty International Airport due to a barrage of challenges, including staffing shortages, outdated infrastructure, and recent technical disruptions. In a bid to address congestion, the Federal Aviation Administration (FAA) has proposed flight reductions at Newark, suggesting a temporary cap on arrivals and departures. These proposed limits would be 28 flights per hour during runway construction and 34 per hour otherwise, lasting through October 25, 2025, to minimize airport delays and cancellations. The situation at Newark has been exacerbated by ongoing communication outages, causing widespread impact on operations. United Airlines, handling nearly 70% of flights at this airport, has faced over 9,000 flight delays since late April 2025. In response, United has slashed about 10% of its daily flights from Newark and is waiving change fees for passengers. Reuters has reported that the airline's challenges are compounded by Newark's operational constraints, leaving United particularly vulnerable amid these disruptions. United's dependency on Newark, following its reduced presence at JFK Airport since 2016, heightens its exposure to these challenges. Although attempts to return to JFK have been difficult, a potential partnership with JetBlue might open doors for United. Additionally, calls are mounting for major investments to modernize FAA’s infrastructure, with U.S. Transportation Secretary Sean Duffy proposing a multibillion-dollar overhaul to address systemic issues, reflecting the broader implications for both United and the industry at large.

ULA's Ambitious Plans to Upgrade Vulcan Rocket for LEO Market

ULA's Ambitious Plans to Upgrade Vulcan Rocket for LEO Market

United Launch Alliance (ULA), the aerospace collaboration between Boeing and Lockheed Martin, is setting its sights on enhancing its Vulcan rocket to compete in the burgeoning low Earth orbit (LEO) satellite launch market. The upgrade aims to enable Vulcan to hold its own against SpaceX's formidable Starship, reflecting the increased demand for satellite launches in this orbital region, as reported by Reuters. The centerpiece of ULA's upgrade plan includes the development of a 'Vulcan Heavy' variant, which would incorporate three Vulcan core boosters to enhance the rocket's performance for LEO missions. Other design configurations under consideration involve innovative propulsion systems designed to optimize launch capabilities. These enhancements are a strategic response to the evolving market dynamics and the anticipated future debut of SpaceX's Starship for large-scale LEO satellite deployments. Currently, the Vulcan rocket has achieved two successful launches and is primarily configured for Pentagon objectives. ULA is focused on executing a steady schedule of launches with both Vulcan and Atlas V rockets in the coming years, a strategy aimed at maintaining robust and reliable mission operations while building towards the ambitious goal of introducing a new Vulcan variant optimized for LEO missions.